SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Clinical trial NCT06222580 · RECRUITING

Trial details

NCT number: NCT06222580
Sponsor: Uma Borate
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia With FLT3/ITD Mutation Acute Myeloid Leukemia With KMT2A Rearrangement Acute Myeloid Leukemia With NPM1 Mutation Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia

Start date: 2024-02-20
Primary completion: 2027-01-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.